Vectorite Biomedical

Vectorite Biomedical EBITDA per Share

The EBITDA per Share of Vectorite Biomedical (4170.TWO) as of Nov 4, 2026 is -0.50 TWD. In the previous year, EBITDA per Share was -0.59 TWD — a change of -15.65% (higher).

EBITDA per Share

-0.50TWD

YoY

-15.65%

Last updated:

EBITDA per Share of Vectorite Biomedical is 2025 -0.50 TWD. EBITDA per Share of Vectorite Biomedical was 2024 -0.59 TWD. It decreases by -15.65% higher compared to the previous year.

The Vectorite Biomedical EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
-1.57 TWD
Jan 1, 2019
-2.14 TWD
Jan 1, 2020
-1.77 TWD
Jan 1, 2021
-0.95 TWD
Jan 1, 2022
0.70 TWD
Jan 1, 2023
-0.37 TWD
Jan 1, 2024
-0.59 TWD
Jan 1, 2025
-0.50 TWD
The Vectorite Biomedical EBITDA per Share history
YEAREBITDA per ShareYoY
-0.50TWD-15.65%
-0.59TWD+61.00%
-0.37TWD-152.83%
0.70TWD-173.16%
-0.95TWD-46.00%
-1.77TWD-17.55%
-2.14TWD+36.72%
-1.57TWD+16.50%
-1.34TWD-22.97%
-1.75TWD-8.88%
-1.92TWD+121.96%
-0.86TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Vectorite Biomedical Stock analysis

What does Vectorite Biomedical do? Xinpin Biomedical Co., Ltd. established Xinpin Biomedical Group with the concept of “preventing problems before it happens” and is headquartered in Taipei, New Taipei. The firm offers a range of services including immune cell collection, processing and storage, cell preparation safety testing, anti-cancer immunity testing, original design manufacturer or contract development and manufacturing organization services, related medical consulting, and laboratory quality management. Its product portfolio features dendritic cell vaccines and natural killer cell preparations designed for cancer treatment. Products are mainly sold domestically. Vectorite Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vectorite Biomedical stock

EBITDA per Share of Vectorite Biomedical is -0.50 TWD in 2025.

EBITDA per Share of Vectorite Biomedical changed from -0.59 TWD to -0.50 TWD, representing a -15.65% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Vectorite Biomedical since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Vectorite Biomedical

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Vectorite Biomedical